Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood test or tumor model predict immunotherapy success?

NCT ID NCT06405230

Recruiting now Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Feb 03, 2026 · Last updated May 23, 2026 · Updated 12 times

Summary

This study looks at new methods to predict whether immunotherapy drugs (dostarlimab and pembrolizumab) will work in people whose non-small cell lung cancer has returned. Researchers will use blood samples, lab-grown tumor models, and special PET scans to see if these tools can forecast treatment response. About 40 participants with advanced or metastatic disease will be enrolled. The goal is to improve how doctors choose treatments, not to test a new cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER NON SMALL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    London, SE1 9RT, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LUNG CANCER NON SMALL CELL